-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Yangtze River Pharmaceutical Co.
, Ltd.
was accepted with posaconazole injections for imitation of 4 types of applications
.
According to data from Meinnet.
com, the global sales of posaconazole in 2020 will exceed US$300 million, and the terminal of Chinese public medical institutions will increase by more than 90% year-on-year in 2021H1
.
At present, the only manufacturers of posaconazole injection are Merck and Jiangsu Osaikang Pharmaceutical
.
Posaconazole is a new generation of triazole antifungal drugs that can be used to prevent invasive Aspergillus and Candida infections
.
The product is developed by Merck and has global sales of more than 300 million U.
S.
dollars in 2020
.
The sales of terminal posaconazole in public medical institutions in China (unit: 100 million yuan) Source: Minet.
com.
China's public medical institutions terminal competition pattern.
According to data from Minet.
com, in recent years, it has been used in urban public hospitals, county-level public hospitals, urban community centers, and towns in China.
The sales of terminal posaconazole in the health center (referred to as the Chinese public medical institution) has grown rapidly.
In 2020, it has been close to 300 million yuan, and it has increased by 92.
11% year-on-year in the first half of this year.
Merck's market share is unique
.
The status of posaconazole products under review.
Source: Meinenet MED2.
0 Chinese drug review database.
Posaconazole has been approved for marketing in oral suspensions, enteric-coated tablets, and injections.
Among them, posaconazole is oral The suspension manufacturer only has Merck, and no company is currently under review.
Posaconazole enteric-coated tablets manufacturers include Organon Pharmaceuticals and Shanghai Xuantai Pharmaceutical, Merck and Sichuan Kelun Pharmaceuticals are under review; Posaconazole enteric-coated tablets Conazole injection production companies include Merck and Jiangsu Osaikang Pharmaceutical, Yangtze River Pharmaceutical, Qilu Pharmaceutical (Hainan), Hainan Better Pharmaceutical and other 8 companies are under review
.
Data source: CDE official website, Minet.
com database
, Ltd.
was accepted with posaconazole injections for imitation of 4 types of applications
.
According to data from Meinnet.
com, the global sales of posaconazole in 2020 will exceed US$300 million, and the terminal of Chinese public medical institutions will increase by more than 90% year-on-year in 2021H1
.
At present, the only manufacturers of posaconazole injection are Merck and Jiangsu Osaikang Pharmaceutical
.
Posaconazole is a new generation of triazole antifungal drugs that can be used to prevent invasive Aspergillus and Candida infections
.
The product is developed by Merck and has global sales of more than 300 million U.
S.
dollars in 2020
.
The sales of terminal posaconazole in public medical institutions in China (unit: 100 million yuan) Source: Minet.
com.
China's public medical institutions terminal competition pattern.
According to data from Minet.
com, in recent years, it has been used in urban public hospitals, county-level public hospitals, urban community centers, and towns in China.
The sales of terminal posaconazole in the health center (referred to as the Chinese public medical institution) has grown rapidly.
In 2020, it has been close to 300 million yuan, and it has increased by 92.
11% year-on-year in the first half of this year.
Merck's market share is unique
.
The status of posaconazole products under review.
Source: Meinenet MED2.
0 Chinese drug review database.
Posaconazole has been approved for marketing in oral suspensions, enteric-coated tablets, and injections.
Among them, posaconazole is oral The suspension manufacturer only has Merck, and no company is currently under review.
Posaconazole enteric-coated tablets manufacturers include Organon Pharmaceuticals and Shanghai Xuantai Pharmaceutical, Merck and Sichuan Kelun Pharmaceuticals are under review; Posaconazole enteric-coated tablets Conazole injection production companies include Merck and Jiangsu Osaikang Pharmaceutical, Yangtze River Pharmaceutical, Qilu Pharmaceutical (Hainan), Hainan Better Pharmaceutical and other 8 companies are under review
.
Data source: CDE official website, Minet.
com database
